Y Intercept Hong Kong Ltd Boosts Position in Ascendis Pharma A/S $ASND

Y Intercept Hong Kong Ltd increased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 104.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,059 shares of the biotechnology company’s stock after acquiring an additional 4,108 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Ascendis Pharma A/S were worth $1,602,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the company. Perceptive Advisors LLC bought a new stake in Ascendis Pharma A/S during the second quarter valued at $166,367,000. Adage Capital Partners GP L.L.C. grew its holdings in shares of Ascendis Pharma A/S by 40.4% during the second quarter. Adage Capital Partners GP L.L.C. now owns 459,606 shares of the biotechnology company’s stock worth $79,328,000 after purchasing an additional 132,201 shares in the last quarter. Marshall Wace LLP increased its position in shares of Ascendis Pharma A/S by 425.5% in the second quarter. Marshall Wace LLP now owns 117,162 shares of the biotechnology company’s stock worth $20,222,000 after purchasing an additional 94,868 shares during the last quarter. Braun Stacey Associates Inc. purchased a new stake in Ascendis Pharma A/S in the third quarter valued at approximately $18,678,000. Finally, Qube Research & Technologies Ltd raised its stake in Ascendis Pharma A/S by 83.4% in the second quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company’s stock valued at $34,700,000 after purchasing an additional 91,412 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $226.10 on Friday. The stock has a market cap of $14.01 billion, a P/E ratio of -50.92, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46. Ascendis Pharma A/S has a fifty-two week low of $118.03 and a fifty-two week high of $242.00. The stock has a 50 day simple moving average of $212.18 and a two-hundred day simple moving average of $201.32.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.76). The business had revenue of $250.71 million for the quarter, compared to analyst estimates of $246.91 million. Sell-side analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

ASND has been the subject of a number of research analyst reports. Raymond James Financial started coverage on shares of Ascendis Pharma A/S in a report on Friday, October 17th. They set a “strong-buy” rating and a $271.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, January 21st. JPMorgan Chase & Co. upped their price objective on Ascendis Pharma A/S from $260.00 to $264.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Royal Bank Of Canada raised their price objective on Ascendis Pharma A/S from $245.00 to $250.00 and gave the company an “outperform” rating in a report on Tuesday, January 20th. Finally, Stifel Nicolaus upped their target price on Ascendis Pharma A/S from $254.00 to $256.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of “Buy” and a consensus price target of $270.76.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.